There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (2)

Short Titles

Short Titles - House of Representatives

Short Titles as Introduced

Free Market Drug Act

Official Titles

Official Titles - House of Representatives

Official Title as Introduced

To establish the National Institute for Biomedical Research and Development.


Actions Overview (1)

Date Actions Overview
09/28/2004Introduced in House

All Actions (3)

Date All Actions
10/08/2004Referred to the Subcommittee on Health.
Action By: Committee on Energy and Commerce
09/28/2004Referred to the House Committee on Energy and Commerce.
Action By: House of Representatives
09/28/2004Introduced in House
Action By: House of Representatives

Cosponsors (9)


Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Related Documents
House Energy and Commerce09/28/2004 Referred to
House Energy and Commerce Subcommittee on Health10/08/2004 Referred to

No related bill information was received for H.R.5155.


Latest Summary (1)

There is one summary for H.R.5155. View summaries

Shown Here:
Introduced in House (09/28/2004)

Free Market Drug Act - Establishes the National Institute for Biomedical Research and Development to provide for the development of drugs, biological products, and devices to: (1) increase the number and medical efficacy of drugs, biological products, and devices on the market; and (2) make the drugs, biological products, and devices available to the public at reasonable prices.

Requires the Director of the Institute to: (1) monitor the results of certain research to identify discoveries that, if subjected to appropriate research and development activities, may be suitable for approval by the Food and Drug Administration (FDA) as drugs, biological products, or devices for use in humans (candidate discoveries); (2) identify candidate discoveries and carry out appropriate research and development regarding such discoveries; (3) establish, review, and revise a plan for the development, testing, and manufacture of candidate discoveries through the Institute; (4) establish priorities among candidate discoveries; and (5)) maintain an Internet site to make available to the public information on activities under this Act.

Allows the Director to identify a discovery as a candidate discovery only if the Federal Government holds, or can reasonably be expected to obtain, a patent on the discovery. Prohibits the Director from transferring ownership of such patent to any non-Federal entity.

Allows civil suits to protect Federal ownership of patents.

Requires the Director to: (1) grant non-exclusive licenses for the commercial marketing of FDA-approved candidate discoveries; (2) establish Federal laboratories to carry out this Act; and (3) establish a fund to provide cash awards for making significant advances in knowledge regarding a disease, disorder, or other health condition.